Companies · Listed company · 🇺🇸

Cytokinetics, Incorporated

CYTK · US

Every figure on this page comes from documents Cytokinetics, Incorporated filed with the exchange, and each one was checked against the document itself before publication. What could not be verified is not here.

The quarters, as filed
QuarterRevenueYoY Net profitYoYNet margin
Jun 2026$29 mn-57.1%$-199 mn-47.9%-694.4%
Mar 2026$19 mn+1125.8%$-206 mn-27.7%-1064.5%
Dec 2025$18 mn+4.9%$-183 mn-22.0%-1030.9%
Sep 2025$2 mn+318.1%$-306 mn-90.7%-15815.0%
Jun 2025$67 mn+26714.9%$-134 mn+6.2%-201.2%
Mar 2025$2 mn+89.1%$-161 mn-19.0%-10220.1%
The ownership tape — last 90 days, from disclosures
▼ Malik Fady Ibraham (EVP Research & Development) sold shares worth $265k · 18 Aug · SEC Form 4

Your desk can read every filing this company makes — before the market opens.

Watch it, and each morning it files something you get the checked numbers, the sources, and red-flag alerts when the quiet numbers move — pledges, ratings, resignations. Ask by name any evening and it is read overnight.

Start free — first week on us →
₹99/month after · research, not investment advice · cancel any time

Data from documents filed with the exchanges, checked against the documents themselves. This page states facts and is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI and verified against filed documents. Terms, disclosures and grievances